The search for an adequate dose involves some of the most complex series of decisions to be made in developing a clinically viable product. Typically decisions based on such dose-finding studies reside in two domains: the first being one of "proof" that the treatment provides evidence of effectiveness. The second concerns the need to choose dose(s) for further development.
Introduction
Identifying the right dose is a key goal in the development of a pharmaceutical compound. Its importance cannot be understated: selecting too high a dose can result in an unacceptable toxicity profile while selecting a dose that is too low increases the likelihood that the compound provides insufficient evidence of effectiveness.
From the perspective of a pharmaceutical company, the decision to undertake confirmatory "phase III" trials is an expensive one. A critical component of this entire decision process is the dose and/or dose regimen, elected for development. Deciding on one or several doses for phase III development is a complex issue, and one that could be better supported through well structure statistical orientation. That is, the provision of frameworks that facilitate the combination of confirming the existence of a drug effect and estimating dose(s) that provide a particular therapeutic response. The possible consequences of adopting non-structured decision processes are discussed next.
Consider a hypothetical compound that would provide a useful benefit to patients, provided an appropriate dose is selected. There are varying degrees of consequences associated with "getting the wrong dose" for such a compound. For example, it may be that only after having marketed this new treatment does it become apparent that the dose is too highthis phenomenon has been documented by the US-FDA in which it was detailed that approximately 10% of drugs approved between 1980-1989 have incurred dose changes -mostly decreases -of greater than 33% [1, 2] . This implies that patients were over-exposed to the drug culminating in the reported side-effects that ultimately led to the dose-reduction. Alternatively, the compound may fail regulatory approval due to a high risk/benefit ratio. In such a setting there are two losses; firstly, patients will never receive this new incremental (or potentially ground-breaking) advancement in medical treatment and, secondly, this missed opportunity will have cost the respective pharmaceutical company millions or possibly billions of US-dollars in lost revenue. A possible "middle" ground is when the pharmaceutical company realises this error part-way through phase III development, in which case, the dose may be changed. This clearly leads to an increased development time and hence cost.
As in many areas of pharmaceutical drug development there is an abundance of guidance documents relating directly, or indirectly, to the important issues of "dose-finding" studies. For example, a dose-finding study should provide evidence of a dose-response relationship [3] . Therein, it is further stated that this evidence ("Proof of Concept", PoC) may be demonstrated via a significant regression effect rather than statistical significance of specific pairwise comparisons -although confirmation of the relative treatment effect and its clinical relevance are required at some stage in the development process. Furthermore, a dose-finding study has clear objectives: to determine the dose for further development and adequate numbers of patients should be included to achieve the study objectives [4] . Statistical testing does play an important role but it is insufficient to provide a P -value as "the" proof of a treatment effect suggesting that statistical models should be used -having been well explained -and that treatment effect estimates, confidence intervals and graphical summarizes should be an Novartis Biom. TR Combining Multiple comparison and modeling No. 2003-08-20 integral component of a data analysis [5] .
In the drug development process, searching for an adequate dose has historically been addressed using two disciplines: multiple comparison approaches and model-based approaches. The former regards the dose as a qualitative factor and generally makes few if any assumptions about the underlying dose-response relationship. The latter assumes a functional relationship between the response and dose, taken to be a quantitative factor, according to a pre-specified model for example, E max , logistic, linear in log-dose model.
When using multiple comparisons, one approach is to evaluate the significance of contrasts between different doses -while preserving the family-wise error rate (FWER) at some prespecified level-α. While such an approach is generally robust, statistical inference is restricted to the set of doses under investigation in the specific study. For the multiple comparison approach, the primary goals are often to identify if there is any evidence of a drug effect and then, following this, what is the minimum effective dose. The definition of minimum effective dose (M ED), is not uniformly agreed, but, following Ruberg [1] , may be considered, "the smallest dose producing a clinically important response that can be declared statistically significantly different from the placebo response". Indeed, in the opening section of ICH-E4 [3] , the purpose of dose-response information is described as finding, "the smallest dose with a discernible useful effect". These two descriptions of "purpose" both contain the suggestion that the M ED should attain a certain assurance that a desired effect is achievable with the selected dose -a concept that is not trivially incorporated into the multiple comparison approach inference structure.
Under an assumed functional dose-response relationship, the model-based approach provides flexibility as the fitted model may be used to provide estimates of primary interest, for example, estimating a dose required to achieve a desired level of response. The validity of such inference may highly depend on having chosen an appropriate model. Thus the dilemma is set, on the one-hand multiple comparisons may be utilised to provide robust statements regarding the existence of a treatment effect but may not be overly informative about which dose(s) to consider for further development. On the other hand, the model-based approach provides considerable flexibility but may be sensitive to the assumed functional form of the dose-response relationship.
In this paper, we discuss a unified strategy that amalgamates multiple comparison and the model-based approaches in the analysis of data arising from dose-response studies. The approach consists of two major steps. We start with a set of potential models for the description of the dose response data. Using multiple comparison procedures, we select the model, if any, out of the candidate set, which best describes the data, while controlling the familywise error rate. Once an appropriate model has been selected, model-based techniques are used to estimate efficiently the target dose of interest.
The paper is organized as follows. In Section 2, we introduce a phase II dose-finding study. Basic concepts on multiple comparison procedures and modeling techniques are reviewed in Section 3. In Section 4 the integration of both strategies is discussed and a new method is derived which accurately estimates the target dose within the dose range under investigation. In Section 5 the phase II example is re-analysed using the newly developed approach. In Section 6 simulation results are then presented and concluding remarks are given in Section 7.
A phase II dose-finding study
This was a prospective randomized double-blind parallel group trial in which a total 217 patients were allocated to either placebo or one of four active doses coded as 0.05, 0.20, 0.60 and 1, n = 43, 42, 46, 41 and 45 respectively. To maintain confidentiality, the actual doses have been scaled to lie within the [0,1] interval and all reference to units are omitted from this manuscript. We consider one of the pivotal variables utilised in the actual analysis conducted for this study which was assumed to be normally distributed and for which larger values of the response indicate a better outcome. A priori the assumption of monotonicity was made, i.e.,
where µ d denotes the expected value of the response for dose d. In order to determine efficacious doses, while maintaining the FWER at the 2.5% one-sided level, a pre-specified closed test (hierarchical) was adopted, in which the highest dose was compared to placebo and if this was rejected at the 2.5 % one-sided level, the next highest dose was then compared to placebo etc., otherwise the inferential testing is then stopped. In Table 1 , the pairwise comparisons of treatment to placebo based on an analysis of variance model with the single explanatory factor treatment, fitted as a categorical variable, are summarized. From the results detailed in Table 1 , it is clear that the formal closed test stopped after having concluded that the top three doses of treatment were statistically significantly different to placebo. The question then arises as the determination of an M ED and the maximum tolerated dose (M T D). Given that all doses were well tolerated, a reasonable conclusion would be that the M T D lies above the dose 1.0. The estimation of the M ED will be the main focus when re-analyzing the example in Section 5.
Modeling and Multiple comparisons
In this section we focus of the introduction of two main themes; some commonly used doseresponse models and statistical inference based on multiple comparison procedure specifically the use of contrast tests.
Dose-response models
The general framework adopted here is that a response Y (which can be an efficacy or a safety variable) is observed for a given set of parallel groups of patients corresponding to doses d 2 , d 3 , . . . , d k plus placebo d 1 , for a total of k arms. Extensions to crossover designs, or other designs involving repeated measures on the same patient, possibly in connection with one or more covariates, will be the topic of future research. We therefore assume the one-way layout
where θ refers to the vector of model parameters, i to the dose group (i = 1 corresponds to placebo), and j to the patient within that dose group.
For the purposes of determining optimal contrasts for model selection, as discussed is Section 3.2, without loss of generality, it suffices to consider a standardized version of the dose-response model. That is, if the function f can be written as
one only needs to consider f 0 . Because the specification of the model testing contrasts is the only information involving f needed prior to the start of the study, it suffices to consider strategies for producing prior estimates for θ 0 for the purpose of designing the model selection tests to be used in the study.
What follows is a selection of models used frequently in dose response analysis. The selection given below is by no means meant to be exhaustive. These models are used and compared to other competing methods with respect to power characteristics. A graphical display for each of these models is shown in Figure 1 , included in Section 6.1.
E max model
The E max model is defined, for θ = (E 0 , E max , EC 50 ) as
E 0 is the basal effect, corresponding to d = 0, E max is the maximum change in effect associated with d, and EC 50 is the dose that gives half of the maximum change. Note that the
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E max model can accommodate both an increase in effect (E max > 0), as well as a decrease in effect (E max < 0).
The standardized E max model is accordingly defined as
The standardized E max model represents the percentage of the maximum change from the basal effect associated with dose d. The advantage is that the specification of the single parameter EC 50 is sufficient to obtain a fully parameterized standardized model f 0 . An initial estimate for EC 50 can be obtained from knowledge of the prior expected percentage of the maximum effect p * associated with a given dose d * . By inverting (3) one obtains
If different (d * , p * ) pairs are available, one can use the average of the corresponding EC 50 as an initial value, or use different estimates EC 50 to determine different sets of testing contrasts for the E max model.
Linear in log-dose model
The linear in log-dose model is defined, for θ = (E 0 , δ) as
where a value c > 0 is added to d to avoid problems with the placebo (d = 0) arm. Typically, c is set to 1. E 0 is the basal effect and δ is the slope associated with log(d + c). As with the E max model, an increasing effect (δ > 0) model will be assumed.
Clearly, the linear in log-dose model is a location-scale model which can be expressed as
, with the standardized model being equal to
so that the determination of the appropriate testing contrast can be done on the basis of the doses alone, and no initial parameter estimates are needed.
Linear model
Again, the testing contrast is shown to be independent of the parameters, as in the linear in log-dose model. The general model formulation and its standardized form are given below, with θ = (E 0 , δ),
Exponential (power) model
This model is intended to capture a possible sub-linear or a slight convex dose-response relationship. It is defined, for θ = (E 0 , δ) as
As usual, E 0 represents the basal level corresponding to d = 0 and δ > 0 (< 0) controls the rate of increase (decrease) in the effect.
Because E 0 is a scale parameter in the exponential model (7), the testing contrast can be determined from the standardized model
being a function of δ alone. An initial estimate for δ can then be obtained from knowledge of the prior expected percentage effect p * associated with a given dose d * . By inverting (8) , and noting that the percentage increase over E 0 is given by
As in the E max model, if different (d * , p * ) pairs are available, one can use the average of the correspondingδ as initial value, or use different estimatesδ to determine different sets of testing contrasts for the exponential model.
Quadratic model
This model is intended to capture a possible non-monotonic dose-response relationship, in either a concave (umbrella or inverted-U) shape, or a convex (U) shape. The full threeparameter model, with θ = (E 0 , β 1 , β 2 ), is defined as
If β 2 > 0, the model corresponds to a U-shape, while β 2 < 0 gives an umbrella-shape. A simple variation of the model above would result from replacing d with log(d) in (10) .
Since d opt = −β 1 /2β 2 is the dose corresponding to the maximum (minimum) response under (10), a necessary assumption in the context described in this paper is d opt > 0, which in turn implies that β 1 and β 2 have opposite signs. The standardized versions of the quadratic model (10), which will be different for the U-and umbrella-shaped models, are then given by 
Logistic model
The logistic model is a four-parameter model, θ = (E 0 , E max , EC 50 , δ), defined as
E 0 is the left-asymptote parameter, corresponding to a basal effect level (not the placebo effect, though), E max is the maximum change in effect from the basal level, EC 50 is the dose that gives half of the maximum change in effect, and δ is a parameter controlling the rate of change with dose in the effect and which has a graphical interpretation as the increment over the EC 50 dose that produces a change in effect of E max /(1 + exp(−1)) ≈ 3E max /4, that is, approximately three-quarters of the maximum change in effect. Note that the logistic model can accommodate an increase in effect (E max > 0), as well a decrease in effect (E max < 0).
Because E 0 and E max are respectively location and scale parameters in the logistic model (12), the testing contrast can be determined on the basis of the standardized model
being, therefore, a function of EC 50 and δ only. As in the E max model, f 0 (d, EC 50 , δ) represents the percentage of the maximum effect E max associated with dose d. Because two unknown parameters are involved, derivation of initial estimates requires, at a minimum, knowledge of the prior expected percentages of maximum effect p * 1 and p * 2 associated with two given doses d *
If more than two (d * , p * ) pairs are available, one can obtain estimates for EC 50 and δ by regressing logit(p * ) on d * : letting b 0 and b 1 represent the corresponding intercept and slope estimates, one could useÊ C 50 = −b 0 /b 1 andδ = 1/b 1 . Alternatively, different estimates for EC 50 and δ could be obtained to determine different sets of testing contrasts for the logistic model.
Contrast Tests
In this section, we fix ideas and notation regarding statistical testing based in single and multiple contrast tests. As mentioned earlier, we restrict ourselves to the one-way layout. Extensions to general linear models are possible, being a topic of current research.
Assume a set M = {M m , m = 1, . . . , M } of M candidate models. Our goal in this section is to select the model which best fits the data, given that it explains the data reasonably well. Each of these models is parametrized through a fixed mean vector µ 
j=1 Y ij /n i represent the average response for patients taking dose i and let
. . , c k ) of known constants subject to c 1 = 0, we are interested in testing the null hypothesis H 0 : c µ = 0 against its one-sided alternative H 1 : c µ > 0, where µ = E(Y ) is the (unknown) vector of true means. Usually we are only interested in one-sided tests, since any parameter specification has an implicit downward or upward trend. The following results are easily generalized to the two-sided case. Note that this type of null hypothesis is slightly more general than the null hypothesis H 0 : µ 1 = . . . = µ k of all means being equal, which is typically found in the context of order restricted inference. In our setting, H 0 will be true for µ 1 = . . . = µ k , as well as for other µ, depending on the particular choice of the contrast vector c.
A single contrast test, with test statistic
, with N = i n i denoting the total number of observations. Under the assumptions of model (1) and H 0 , the test statistic T has a central t−distribution with N − k degrees of freedom. When H 0 is not true, T follows a non-central t−distribution with non-centrality parameter
Let us now come back to the set M of M candidate models. Each of these models translates to a single contrast vector c m , which can be used to test for a significant dose response effect. Our focus is on simultaneous inferences about the parameters c m µ. Let H = {H 
One way to combine the test statistics T m into one decision rule is to take the best contrast, i.e., to take the maximum
By construction of the individual hypotheses H m 0 , we therefore assess, which parameter configuration best fits the available data. If T max > c for an appropriate critical value c, the associated parameter configuration is significant and we select the related model M m and parameter vector θ m for further investigation, where m = argmax m T m . If P m is the associated (adjusted) P −value of T m , an equivalent decision is obtained through min m P m < α.
By performing several tests simultaneously, however, the probability of at least one falsepositive increases in M . In order to control the familywise error rate at a pre-assigned level α, the critical value c has to be defined such that
Clearly, choosing c = t ν,1−α from the univariate t−distribution is not appropriate. We instead consider the joint distribution of the vector T = (T 1 , . . . , T M ). Under the classical ANOVA assumptions given above, it follows that under
is M −variate t−distributed with ν = N − k degrees of freedom and correlation matrix R = (ρ uv ) uv , where
By using the multivariate t−distribution we obtain P −values and critical values, which automatically incorporate the necessary multiplicity adjustment. Thus, the strong control of the FWER is guaranteed at level α without additional computations. In addition, given the parametric assumptions of the original data, we also incorporate the correlation between the contrasts in a natural way. Since these correlations also reflect the association between various parameter configurations, the entire information contained in the f 0 m and the θ m are kept in the final evaluation. As one can easily imagine, some of the resulting contrasts may be highly correlated. The particular models at the given parameter specifications are thus virtually indistinguishable and we will either select all or none of them. We come back to this problem later. method is abbreviated through MCP-Mod, since it combines multiple comparison procedures with modelling techniques. We assume the existence of several candidate parametric models and use multiple comparison techniques to choose the one most likely to represent the underlying dose-response curve. This is implemented in several steps. The first step consists of computing optimum contrast coefficients, once the set of potential models has been identified, as shown in Section 4.1. In the second step we evaluate the significance of the individual models in terms of corresponding single contrast tests. A good candidate model is chosen as the one with the most significant contrast test. Such procedure allows the selection of the most adequate dose-response model, while preserving the familywise error rate, as shown in Section 4.2. Finally, the selected model is then used to produce inferences on adequate doses, employing a model-based approach. In Section 4.3 different decision rules for estimating the minimum effective dose are introduced.
Choice of contrasts
In this section we consider the problem of determining the "best" contrast associated with a given model function f (d, θ), in the sense that, when that model is correct, it maximizes the chance of rejecting the associated null hypothesis.
Initially we consider the case of two-sided alternatives. It is easy to show that the power of this two-sided test increases with the absolute value of the non-centrality parameter τ = τ (c). Therefore, to maximize the probability of identifying model f as the correct one, one should choose c opt (f ) such that
Clearly, such a c opt (f ) is only defined up to a scale factor, because g(c, µ) = g(λc, µ), and so if c opt maximizes g(c, µ), then so does λc opt , ∀λ ∈ R. For uniqueness, we will require here that c opt = 1. Note that such a c opt is still not unique, because ±c opt are both optimal. As discussed below, these will correspond to the optimal contrast vectors for the two possible one-sided tests. For two-sided tests, however, it is irrelevant which c opt is chosen.
The two one-sided t-tests associated with H 0 have alternative hypotheses H + 1 : c µ > 0 and H − 1 : c µ < 0. The power of the first test increases with the value of the non-centrality parameter τ , while that of the second increases with −τ . Let ±c opt 2s represent the solutions corresponding to the two-sided test satisfying (16) and, without loss of generality, assume that (c opt 2s ) µ > 0. Then it follows that c opt 2s is the optimal contrast for the one-sided test corresponding to H + 1 and −c opt 2s is the optimal contrasts corresponding to H − 1 . To see that, assume that there exists a c opt + = c opt 2s that maximizes τ (c). This would imply that τ (c opt + ) > τ (c opt 2s ), which, in turn, would give g(c opt + , µ) > g(c opt 2s , µ), a contradiction, since c opt 2s maximizes g(., µ). A similar argument applies to H − 1 .
Assuming that there exists a standardized version
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Therefore, c opt (f ) = c opt (f 0 ) and it suffices to consider the problem of finding the c opt corresponding to the standardized model f 0 .
In the rest of this section we discuss the calculation of c opt under balanced sample size allocation. In this case, a closed-form solution exists. In unbalanced situations, only approximate solutions or numerically-optimized solutions are available, being a topic of current research.
Assume that the sample sizes are the same per treatment group, that is, n i = n, i = 1, . . . , k.
In this case, under the restriction c = 1, g(c, µ) = n(c µ) 2 , so it suffices to maximize (c µ) 2 in c. It follows from the Cauchy-Schwarz inequality and our assumptions on c that
whereμ = µ 1/k. It follows from (17) and the discussion above on the sufficiency of considering the standardized model that
Note that c opt depends only on the parameters of the standardized model.
Model selection
Once we have an optimal contrast test for each model in M, we proceed as follows. At a first step, we evaluate the significance of the individual models in terms of the corresponding single contrast tests within an ANOVA framework, i.e., where the dose is taken as a qualitative variable. Every single contrast test translates into a decision procedure, whether a selected dose-response curve is significant given the current data, while controlling the (familywise) type I error rate α. Note that the definition of µ 0 m -and thus the derivation of the contrast coefficients -is given prior to the experiment and is therefore free from the actual data. This ensures, that the contrast tests indeed maintain the nominal size α. In a second step, a good candidate curve is chosen as the one with the most significant contrast test, given that its individual multiplicity adjusted P −value is less than α. Such procedure allows the selection of the most adequate dose-response relationship, while preserving the familywise error rate, which includes a correction for multiplicity. On a less stringent level we can even argue that the generating model behind the selected dose-response curve is either the true underlying model or, at least, it lies close to it. Note that we will not be able to select a specific candidate model at confirmatory level α for several reasons. First, two (or more) models might lead to virtually the same dose-response curve within the dose range under consideration. Thus, contrast tests are not able to discriminate between these models, if a selected collection of means µ 0 m = (µ 0 m1 , . . . , µ 0 mk ) is true for more than one model. Second, if we let, for example, the empirical mean of the last dose group d k be unbounded, it is easy to see that any contrast test (and thus any test on a specific dose-response curve), will be highly significant, even if the contrast coefficients (and thus the parameters settings) are poorly chosen.
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Note that if we do not obtain any significant contrast at all, we hardly can pursue any further research for a good dose within the set M of candidate models. But such a result does not necessarily mean that the compound has no effect at all. In general we will assess that there was not enough evidence to get statistical significance. Possible reasons could include small sample sizes or high variance. In addition, the set M might have been poorly chosen, such that the candidate models does not fit the true curve (perhaps an umbrella-shaped curve) -although in such cases the compound has an pronounced effect and may be far from ineffective, as suggested by the insignificant P −value. Note that the use of a standard trend test, such as the likelihood ratio test of Bartholomew, does not yield substantially better results for the PoC at this first stage. As shown in the simulations later in Section 6, the global testing part of MCP-Mod described here has virtually the same power as the likelihood ratio test over a broad range of the alternative hypothesis region.
If at least one model is significant, though, we obtain a set of good models, each of which fulfills the significance criterion of the adjusted P −value being less than α. This set may be regarded as a reference set of models, which includes the most significant model with the minimum P −value among all models initially considered in M. The problem of how to proceed further, if the resulting reference set contains more than one model depends on the user's decision. While all models included in this reference set are statistically significant at the familywise error rate α, the one with minimum P −value is the most likely one to be the true model or at least to approximate the true model satisfactorily. In practice, it might be hard to decide upon the best model. For example, if the second best model has a P −value lying close to the minimum P , both models might be worth later consideration. In such cases, additional analyses or data collection might be advised before going ahead with one single model. In particular, the second best model perhaps requires less parameters for its specification and may thus lead to numerically more stable fits to the data. Once a particular model has been selected, it is used to produce inferences on adequate doses, employing standard model based approaches (as discussed in Section 4.3). In contrast to a direct application of a model based approach, the preliminary steps of our approach do take care of possible model misspecifications and include the associated statistical uncertainty in a rigorous hypothesis testing environment. Thus, the approach considered in this report has the advantage of leading to a quantitative measure of reliability for selecting an adequate dose-response model. An important point is the selection of a good candidate set M. Such a selection is crucial for the quality and the interpretation of the results. The selection of the candidate set M could, or better, should, be based on the user's beliefs about the functional relationship and the amount of information available at the given time point. The set M includes either single or multiple parameter configurations for each model under investigation. Such flexibility in the selection process suggests that the best way to proceed is to include as many candidate models as possible. However, such a straightforward approach bears two serious drawbacks. First, an increasing number of models necessarily implies that, on average, any two candidates are becoming less distinguishable and thus the discriminant power of the contrast tests is markedly reduced. Second, multiplicity adjustment has to be taken care of and any new model included in M will increase the penalty (but note that the multiplicity No. 2003-08-20 adjustment is also a function of the correlation between the various models and therefore the penalty is not unbounded as one might first guess).
As a numerical example, we consider the six models introduced in Section 3.1. Consider the correlation between these models for a typical parameter configuration in Table 6 in Section 6. The problem of several models tending to similar conclusions becomes evident when looking at the individual correlations: the correlation between the linear model and both the exponential and the log-linear models lies around 0.98. Even the quadratic model shows a correlation of at least 0.45 with any of the other models. These high correlations also ensure that the multiplicity adjustment is not too costly in terms of α-penalty. Computing the 95% critical value from the hexavariate t−distribution gives c = 2.023, which corresponds roughly to a Bonferroni adjustment with two models. By comparison, the unadjusted critical value from the univariate t−distribution is c = 1.658 and the Bonferroni adjusted critical value for all six models is c = 2.428.
Dose selection
Once the overall dose response relationship has been established through the proof of concept and an adequate model has been selected, the third and final step of MCP-Mod consists of (i) fitting the selected model to the data and (ii) estimating adequately the target dose of interest.
In the following discussion we restrict our attention to the estimation of the minimum effective dose (M ED), although the ideas can be applied to other target doses as well. A minimum effective dose is defined as the smallest dose, which (i) shows a clinically relevant and a statistically significant effect. A stronger requirement ensures that in addition (ii) all doses above the M ED are also clinically relevant and statistically significant. In practice, requirement (ii) will typically only apply to monotone dose-response profiles.
Recall from Section 3.2 that D = {d i , i = 1, . . . , k} is the dose set under investigation. Let further ∆ denote the clinically relevant difference, i.e., the smallest relevant difference, by which we expect a dose to be better than placebo. It was not necessary to include ∆ in the PoC described in the previous section. By definition, a PoC is performed to assess a potential dose response relationship throughout the dose response range under investigation and to select an appropriate model for fitting the data. For the dose estimation step, however, a clinical relevance parameter is taken into account to ensure that the potential dose indeed yields a clinically relevant effect. Typically, estimation of M ED in this environment is conducted by applying adequate multiple testing techniques, see [6] .
In contrast, model based approaches allow In the following we focus on definition (19) and propose three different rules for estimating the true M ED. Denote by L d (U d ) the lower (upper) 1 − 2γ confidence limit of the predicted value p d at dose d after fitting the model f (., θ) to the given sample X. Note that the dose estimation step has the goal of estimating the target dose as precise as possible. Thus, the choice of γ is not driven by the purpose of controlling type I error rates, in contrast to the selection of α for controlling the FWER for the PoC. The following estimates are investigated further by simulation in Section 6:
Note that in some instances no M ED is estimated with any of the three decision rules. As seen later in the simulation section, there is no uniformly best rule among these three candidates. But due to this inequality, rule (A) tends to underestimate the true M ED in general while rule (C) tends to select too high a dose. Some advice on the selection of γ and the decision rules are provided in Section 6.
Once the MED is estimated using one of the methods above, it is important to assess its precision, for which a confidence interval is generally the most useful tool. Bootstrap methods can be used to derive such a confidence interval. One possibility is to implement a full, nonparametric bootstrap approach, in which the patients within each dose group are re-sampled, with replacement, and the whole dose-finding procedure is repeated, yielding a bootstrap For the model and data scenarios considered here, θ is asymptotically normally distributed. The parametric bootstrap approach then consists in re-sampling the parameter vector θ from its approximate distribution N ( θ, Σ) and using these values to derive a bootstrap sample of MED values. In either case, the bootstrap sample of MED values would be used to derive an appropriate confidence interval for the MED.
In some cases, fitting the model with the highest T −value does not work because of numerical instabilities. Such problems occur, for example, when the model to be fit contains many parameters in comparison to the number of doses, or when the doses are not spread evenly throughout the dose range under investigation. In such instances, estimating the M ED from the most promising model is simply not possible. To circumvent this problem, one can select the second best model (assuming that it is significant at level α), fit it to the data and estimate the target dose if the fit was successful and otherwise continue with the next best model. An alternative is not to use the T −statistics for the model selection process. For example, one could compute an appropriate information criterion for those (and only those) models which are significant at level α. Such information criteria, as the AIC for example, typically include a penalty term for the number of model parameters and they possibly ensure that, once selected, a model indeed provides a numerically feasible fit to the data.
Re-anaylsis of the phase II study
In this section, data presented in Section 2 are re-analysed using the MCP-Mod approach outlined in Sections 3 and 4. The set of candidate models includes: E max , linear in log-dose, linear, exponential and quadratic (inverted U-shape). Based on preliminary discussions, the logistic model is not included in this candidate set.
For the linear and linear in log-dose (setting c = 1) models, the values of the dose determine the optimal contrasts. For the three remaining models, additional parameters require specification. Methods for obtaining initial estimates have been discussed throughout Section 3, based on the corresponding standardised models.
In the case of the E max model we require an estimate of the EC 50 that is, the dose providing half of the maximum change. For the purposes of illustration, we assume that this value is 0.20. In determining the contrast coefficients for the exponential model, we assumed that the dose of d * = 0.2 corresponded to a 50% improvement over the placebo response, which led to an initial estimate for the rate of increase δ = 0.5. The contrast coefficients for the quadratic model can be obtained by using the value for EC 50 specified above in combination with Equation (11), i.e., d * = 0.2, p * = 0.5.
Based on the above specifications, and for simplicity assuming equal sample sizes per group, the optimal contrasts (each entry independently rounded to 3 decimal places) and correlations are given in Table 2 . Using the above contrast coefficients, a summary of the multiple-comparison component of this approach, ordered by the magnitude of the observed t-value, is given in Table 3 . The onesided unadjusted (raw) P -values are presented and are accompanied with the corresponding adjusted one-sided P -values from the multivariate t-distribution. All contrast tests with an adjusted P -value less than 0.05 or equivalently with a t-value greater than 1.930 can be declared statistically significant having maintained the FWER at level 5%. Clearly all contrast tests are highly significant at the 5% level. Following the approach outlined in Section 4.3, the E max model is the first model to be considered for the dose-selection component of this analysis. A summary of the parameter estimates based on the E max fit to these data is detailed in Table 4 .
In Section 4.3, three competing methods for selecting a dose were introduced. To illustrate the methodology, each of these three approaches are implemented for γ ∈ {0.05, 0.10, 0.15, 0.20, 0.25}, and the resulting selected doses are summarized in Table 5 .
Now suppose that we had intended to apply criterion B with γ=0.05, and we set the clinical relevance threshold (∆) to be 0.4, i.e., we wish to determine the smallest dose such that the lower limit of the 90% confidence interval for the predicted response is greater than zero and that the point estimate is greater than 0.4. Based on the details in Table 5 , the selected dose is 0.28.
Let us assume that the set of active dose levels used in this study (=0.05, 0.2, 0.6, 1.0) define the only doses for which it is possible to manufacture the experimental treatment.
In this case, we observe that the next highest dose neighboring the selected dose level is 0.6. A pragmatic approach could then be to suggest that the implementation of the MCPMod approach lead to dose 0.28 being determined as the minimum dose that attains the prescribed conditions for selection. In principle, any dose lying above 0.28 may be defined as an acceptable dose, provided that the gain in efficacy does not result in an unacceptable increase in the risk of adverse events: the risk-benefit ratio. If, on the other hand, this study had been undertaken with the aim of manufacturing a dose as close as possible to that selected, the dose level either equal to 0.28 or in close proximity to 0.28 would then be determined as the dose used for further drug development -provided the safety profile for such a dose would be deemed appropriate.
Simulation results
In this section we investigate, via simulation, the performance of the MCP-Mod dose finding methodology described in the previous sections. Two main aspects of the methodology will be studied here:
• its power to detect the existence of some type of dose-response relationship, the proofof-concept (PoC) performance and
• its ability to, at the end, choose a dose close to the desired level (taking into account both statistical significance and clinical relevance), the dose selection performance.
Other classical dose finding methods based on multiple testing procedures were also used in the simulations for comparison with the MCP-Mod method proposed here, with regard to the PoC performance. Because model-based dose selection methods can choose any value on a continuous scale, they are not directly comparable to classical dose finding methods based on multiple comparisons alone, which can only select the dose from within the set of levels under investigation. Therefore, the dose-selection performance is only investigated for the MCP-Mod dose finding method.
Design
The study design used for the simulations was based on that of the case study of Section 2:
• dose levels: d = 0, 0.05, 0.2, 0.6, and 1
• five parallel groups, with a single endpoint measured per patient
• balanced sample size allocation with n patients per dose group and no drop-outs All of these shapes have the property that at d = 0 the response value is about 0.2 and, with the exception of the constant shape, all have a maximum response of about 0.8 within the interval [0, 1] (that is, a maximum dose effect of about 0.6). Figure 1 displays the doseresponse profiles for the nine shapes listed above. A total of 10,000 simulated trials were generated for each shape × sample-size combination.
The constant shape is included to evaluate the performance of the MCP-Mod method in terms of preserving the nominal type I error rate for PoC determination. Shapes 2 through 7 have been described in Section 3.1 as typical dose-response models used in practice. As before, they will also form the set of candidate models for the linear contrast tests. The last two shapes, 8 and 9, are included to evaluate the performance of the MCP-Mod method under model misspecification: they do not quite correspond to any of the model shapes in the candidate set, though can be approximated by some of the models in there.
The test contrasts used in the simulations for the six models in the candidate set (E max , linearlog, linear, exponential, quadratic, and logistic) were obtained using the true parameter values for the corresponding standardized model (e.g., EC 50 = 0.2 for the E max model).
The resulting contrasts are presented in Table 6 . There is considerable correlation between Table 6 : Test contrasts for models in candidate set, with corresponding pairwise correlations. some of the test contrasts (e.g., linear and exponential) indicating that it may be hard to discriminate between such models in the simulations. 
Proof-of-concept performance
For the purpose of evaluating the PoC performance of the MCP-Mod method, the response standard deviation was set at σ = 1.478, which, for a sample size of n = 75 patients per arm, gives a power of 80% for the pairwise test between two doses at the maximum effect of δ = 0.6. Table 7 gives the simulated probabilities of establishing PoC for the different methods under the various shape × sample-size combinations.
We included the likelihood ratio test (LRT) [7] and the step contrasts [8, 9] as competitors to the MCP-Mod. The LRT is known to be one of the most powerful tests for trend throughout the order restricted alternative region µ 1 ≤ . . . ≤ µ k . In contrast to MCP-Mod, the LRT is designed for the PoC only and thus does not give any information about the underlying dose response shape. Extensive mathematical details are given in [10] . The step contrasts are a powerful alternative to the LRT. It can be seen that the step contrasts match exactly the corner vectors of the polyhedral cone described through the relationship µ 1 ≤ . . . ≤ µ k . Thus they span the order restricted space of interest. The step contrasts are particularly powerful for finding the change point in a series of treatment means [8] . For our simulations we used the multivariate t-distribution to compute the critical values. Table 7 : Proof-of-concept probabilities for the different dose-finding methods, under the shape × sample-size combinations. The type I error rate is well controlled at its nominal level of 5% for all sample sizes. The logistic shape has the highest PoC power and the convex shape the smallest. The PoC power values for the other shapes are of comparable magnitude. In particular it is seen that MCPMod behaves very similar in power compared with the LRT. The LRT is slightly better for the convex shape. This is because we did not include the convex shape as a model in the candidate set M for MCP-Mod. Had included such model in the candidate set, the advantage of the LRT would likely vanish. Instead, MCP-Mod seems to be slightly more powerful for the linear-log, linear and logistic shapes. MCP-Mod is considerably more powerful than the LRT for the quadratic and the double-logistic shapes, since the LRT is not designed for such downturns at higher doses. Both the MCP-Mod and the LRT are more powerful than the step contrasts.
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The PoC results also provide information about the ability of the contrast tests in the MCPMod method to discriminate between the models in the candidate set. Table 8 gives the simulation probabilities of choosing the correct model for the six models in the candidate set (e.g., the probability of the E max model contrast yielding the largest t-statistic when in fact this is the correct model). The quadratic model has the best discrimination power, which is not surprising since, as seen in Table 6 its associated contrast is the least correlated with the remaining model contrasts.
The linear-log and linear model are the hardest to identify, which is again consistent with the correlations observed in Table 6 . Because models which can represent similar dose-response profiles will likely lead to similar dose selections in the second stage of the method, the discrimination among highly correlated models is less critical than among the less correlated ones. This issue will be further explored in Section 6.3.
Furthermore, as described in Section 4.3, the model with the highest t-statistic in the contrast tests will not necessarily be the one that ends being used to select the dose(s), as it may not converge in the model fitting step. Therefore, it is also relevant to consider the probabilities of correctly choosing the model for the actual dose selection, which is discussed in the next section.
Two of the shapes used in the simulations, the double-logistic and the convex, do not correspond to any of the models included in the candidate set. It is interesting to consider which of the candidate models, if any, or chosen in the contrast tests, when these shapes were used. Table 9 gives the corresponding selection probabilities for the models in the candidate set (and the probability of none of the models being selected).
It is clear from Table 9 that the double-logistic shape is approximated by either the quadratic or the logistic shape, while the convex shape is approximated by the exponential model. The discrimination among the different model increases with sample size, as expected, being quite small, for the scenarios considered here, for sample sizes smaller than 50. 
Dose selection performance
For the purpose of evaluating the dose selection performance of the MCP-Mod algorithm, a response standard deviation of σ = 0.65 was used. This is consistent with the estimated residual standard deviation observed for the case study of Section 5 and provides a more realistic value for the simulations. As in Section 5, a clinically relevant effect of ∆ = 0.4 was adopted in the dose selection algorithms described in Section 4.3. The confidence levels (= 100(1 − 2γ)%) used for these algorithms in the simulations were 50%, 60%, 70%, 80%, and 90%.
The simulation PoC power values under the different shape scenarios, using the new σ, are given in Table 10 (only the MCP-Mod method is considered in this section). As expected, 1.000 1.000 1.000 1.000 1.000 1.000 1.000 100 0.048 1.000
1.000 1.000 1.000 1.000 1.000 1.000 1.000 150 0.057 1.000
1.000 1.000 1.000 1.000 1.000 1.000 1.000
the power values are considerably larger than in Table 7 , because of the 56% reduction in σ. The type I error rate is well controlled at the nominal 5% level and by n = 50 all shapes result in almost certain PoC detection.
It is also useful to look at the probabilities of selecting the correct model in the contrast testing step, as well as the probabilities of using the correct model for the dose-selection step (recall that, because of potential convergence problems, the two need not be the same). Tables 11 and 12 give the corresponding probabilities. The models corresponding to the less correlated contrasts are well discriminated at the contrast test step, especially for larger sample sizes. The linear-log, linear, and exponential models are not as well discriminated due to the higher correlation between their corresponding contrasts, as discussed before.
For all but the logistic model, there is an increase in the probability of choosing the correct model compared with that of selecting it based on the contrast tests. The basic problem with the logistic model in the simulation scenarios used here is that doses were not chosen to well characterize the shape of the logistic curve. Because there only five doses (two of them, 0 and 0.05, fairly close to each other) and four parameters to be estimated in the logistic model, the unfavorable design led to frequent convergence problems when the logistic model was selected by the contrast testing step. As a result, this model ended up being used for dose selection considerably less frequently than it was initially selected by the contrast tests.
The selection probabilities for the models in the candidate set for the double-logistic and convex shapes are presented in Tables 13 (contrast test) and 14 (dose selection). The distribu- Table 13 are similar to, though more pronounced than, the ones observed in Table 9 : the double-logistic shape tends to lead to the selection of the quadratic or the logistic models, while the convex shape favors the selection of the exponential model. The logistic model was frequently selected based on the contrast tests for the double-exponential shape, but was rarely the model actually used for dose selection, due to convergence problems. Table 15 below gives the target doses to achieve the desired clinically relevant effect of 0.4 (difference with respect to placebo) for the eight different shapes considered for dose selection. Due to the large number of shape × sample size × γ-level combinations, we only present the dose selection simulation results for a subset of the scenarios investigated. Figures 2 and  3 include the boxplots of the selected doses in 10,000 simulated trials using methods A, B, and C, for all shapes (except the constant), γ = 0.2 (corresponding to a 60% level confidence interval), and n = 25 and 75. The dashed lines in the plots indicate the corresponding target doses.
It is clear from the figures that method A tends to underestimate the target dose, method C tends to overestimate it, and method B estimates the target dose more consistently. The precision of the methods is considerably enhanced when the sample size increases from 25 to 75. It should be noted, though, that the dose design used in the simulations was intended for a multiple comparison determination of the MED, and not for modeling. A more suitable choice of doses with modeling in mind would yield considerably better results, for the same overall sample sizes. This is a topic of current and future research.
The precision of the dose selection algorithms vary considerably with the underlying doseresponse shape. The quadratic, convex and exponential shapes tend to lead to greater precision (for the particular scenarios used here, but not in general), while the remaining shapes gave similar dispersions for the dose estimates.
To evaluate the impact of the γ-level in the performance of the dose selection algorithms, the boxplots of the selected doses using γ = 0.2 (80% confidence interval) are included in Figures 4 and 5 . The overall conclusions based on the boxplots corresponding to γ = 0.1 are similar to the ones for γ = 0.2, but the under-and over-estimation of methods A and C becomes even more evident. Method B continues be the most consistent and does not have its performance much affected by the change in γ.
Similar results are observed for the other sample sizes and values of γ. We conclude that method B seems preferable to the other methods. The dose-selection step offers additional and useful knowledge about the underlying dose-response profile that is not possible with traditional multiple comparison dose selection methods. Greater precision in the estimation of the model would be obtained if more suitable designs were used. In this paper we have described a unified strategy for analyzing dose finding studies, including the testing of proof-of-concept (PoC) and the selection of one or more doses to take into further development. The proposed methodology combines the advantages of the multiple comparison and modeling approaches, consisting of a multi-stage procedure. PoC is tested in the first stage, using multiple comparison methods to identify statistically significant contrasts corresponding to a set of candidate models. If PoC is established in the first stage, the best model is then used for dose selection in subsequent stages.
We have shown how to determine optimal contrasts motivated by an assumed underlying dose-response model and have given detailed descriptions of many commonly used doseresponse models, including their standardised versions. It was shown that these standardised models are the pivotal functionals required in determining optimal contrasts, and methods for determining initial values for the required parameters were discussed. Different model-based dose-selection methods, incorporating both statistical significance and clinical relevance, were presented and evaluated via the analysis of real and simulated data.
The proposed method, termed MCP-Mod, is seen to maintain the FWER at its nominal level, has PoC power comparable to the LRT under monotone dose-response settings, and is better than the LRT under non-monotone scenarios, provided the set of candidate models is broad enough. The clear advantage of this new approach, in comparison to more traditional multiple comparison dose finding methods, is its added flexibility in searching for and identifying an adequate dose for future drug development.
Several extensions of the proposed methods are possible and a number of issues remain topics of ongoing and future research. We restricted ourselves in this paper to the case of balanced one-way ANOVA designs for parallel groups. It is straightforward to extend the methods described here to handle unbalanced sample size allocation, as well as more general linear models, with the inclusion of covariates and/or factorial treatment structures. The use of the approach described here in the context of repeated measures (e.g., cross-over designs, titration studies, etc) requires more research and development, including extensions to mixed-effects models. Another straightforward extension is to use more powerful stepwise multiplicity adjustments instead of the single-step procedures proposed in this paper. Other research questions include the sensitivity of the methods to the choice of initial values for the standardized models, the investigation of designs more suitable for dose-response modeling, and the development of statistical software implementing the methods and procedures described herein.
